GRFS logo

Grifols S.A. (GRFS)

$8.63

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on GRFS

Market cap

$5.93B

EPS

0.69

P/E ratio

10.9

Price to sales

0.59

Dividend yield

3.907%

Beta

0.749386

Price on GRFS

Previous close

$8.73

Today's open

$8.65

Day's range

$8.59 - $8.73

52 week range

$6.96 - $9.77

Profile about GRFS

CEO

Jos Ignacio Buenache

Employees

25247

Headquarters

Sant Cugat del Valles, Barcelona

Exchange

Nasdaq Global Select

Shares outstanding

687554908

Issue type

American Depository Receipt

GRFS industries and sectors

Healthcare

Pharmaceuticals

News on GRFS

Grifols: Plasma, Profits, And Recovery Gathering Momentum

Grifols remains a speculative 'BUY' with a €20/share price target, offering over 20% annual upside if growth continues. GIKLY has delivered strong 3Q26 results: revenue above €2B quarterly, EBITDA up 10%, net profit up 28%, and leverage now below 4x. Strategic expansion into Egypt is expected to diversify plasma sourcing, reduce costs, and support margin improvement through geographic diversification.

news source

Seeking Alpha • Nov 3, 2026

news preview

Grifols Q3 Earnings Call Highlights

Grifols NASDAQ: GRFS reported third-quarter 2026 results marked by revenue growth, expanding profitability, stronger free cash flow and lower leverage, while management reiterated its full-year financial targets despite continued weakness in China's albumin market.

news source

MarketBeat • Nov 2, 2026

news preview

Grifols says Canada plasma license suspension has no impact

Spanish drugmaker Grifols said Health Canada's decision to suspend its license to collect plasma at its Taylor Avenue ​facility in Winnipeg had no impact on operations.

news source

Reuters • Sep 24, 2026

news preview

GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks presents investors with the better value opportunity right now?

news source

Zacks Investment Research • Sep 24, 2026

news preview

Grifols: Better Plasma Economics Can Unlock A Discounted Equity

Grifols is shifting to regional plasma sourcing, aiming for durable cash generation over headline catalysts like a U.S. listing or refinancing. I see improved cash flow as contingent on better sourcing economics, higher network productivity, and incremental plasma protein revenues, not just revenue growth. Despite a 30%+ EV/EBITDA discount to peers, GRFS's value hinges on operational improvements and cash conversion, not simply low multiples.

news source

Seeking Alpha • Sep 17, 2026

news preview

GRFS or SDZNY: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Drugs stocks are likely familiar with Grifols (GRFS) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?

news source

Zacks Investment Research • Sep 8, 2026

news preview

Oakmark International Small Cap Strategy Q2 2026 Portfolio Update

The portfolio's return was 5.34% (net) for the reporting period. We initiated the following positions: Birkenstock Holding, Dormakaba, Hiab, Reply, SATS Ltd., and Scout24. We eliminated the following positions: Grifols Cl B ADR and Sopra Steria Group.

news source

Seeking Alpha • Aug 15, 2026

news preview

Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency

BARCELONA, Spain, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the completion of the clinical portion of SPARTA (Study of ProlAstin-C Randomized Therapy with Alpha-1 augmentation; NCT01983241), its phase 3 outcomes study evaluating the clinical efficacy and safety of two dose regimens of Prolastin®-C (Alpha1-Proteinase Inhibitor [Human] modified process) in patients with emphysema associated with alpha-1 antitrypsin deficiency (AATD), also known as alpha-1.

news source

GlobeNewsWire • Aug 10, 2026

news preview

Grifols Q2 Earnings Call Highlights

Grifols NASDAQ: GRFS said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, improving free cash flow and progress in its plasma-sourcing strategy.

news source

MarketBeat • Jul 28, 2026

news preview

Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins

BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that the first patients have been dosed in two separate Phase 3 trials aiming to expand the U.S. labels for its signature immunoglobulin therapeutics, GAMUNEX®-C, an intravenous immunoglobulin (IVIg), and XEMBIFY®, its subcutaneous immunoglobulin (SCIg).

news source

GlobeNewsWire • Jul 16, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Grifols S.A.

Open an M1 investment account to buy and sell Grifols S.A. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in GRFS on M1